Calidi Biotherapeutics Files 8-K

TL;DR

Calidi Biotherapeutics filed an 8-K on Jan 10, 2025. Nothing major, just standard reporting.

AI Summary

Calidi Biotherapeutics, Inc. filed an 8-K on January 10, 2025, reporting other events and financial statements. The company, formerly known as First Light Acquisition Group, Inc. until April 6, 2021, is incorporated in Delaware and headquartered in San Diego, California.

Why It Matters

This filing provides an update on Calidi Biotherapeutics' corporate activities and financial reporting, which is important for investors to stay informed about the company's status.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report and does not appear to contain any significant new information that would immediately impact the company's risk profile.

Key Players & Entities

• Calidi Biotherapeutics, Inc. (company) — Registrant
• January 10, 2025 (date) — Date of Report
• First Light Acquisition Group, Inc. (company) — Former Company Name
• April 6, 2021 (date) — Date of Name Change
• Delaware (jurisdiction) — State of Incorporation
• San Diego, California (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — ch Registered Common stock, par value $0.0001 per share CLDI NYSE American LLC

Filing Documents

• form8-k.htm (8-K) — 42KB
• 0001493152-25-001711.txt ( ) — 216KB
• cldi-20250110.xsd (EX-101.SCH) — 3KB
• cldi-20250110_lab.xml (EX-101.LAB) — 33KB
• cldi-20250110_pre.xml (EX-101.PRE) — 24KB
• form8-k_htm.xml (XML) — 4KB

Financial Statements

Financial Statements The Consolidated Financial Statements for the Fiscal Year ended December 31, 2023 as initially filed with the Company's annual report on Form 10-K ("2023 Annual Report") are being refiled in this Current Report on Form 8-K to give retroactive effect to the Company's 1-for-10 reverse stock split of the shares of the Company's Common Stock, par value $0.0001 per share, effective on July 15, 2024 (the "Reverse Stock Split"). Attached as Exhibits are the auditor report and the consolidated financial statements, reflecting the Reverse Stock Split. This Form 8-K is being filed only for the purposes described above, and all other information in the 2023 Annual Report remains unchanged. Except for the matters noted above, the Exhibits to this Current Report do not reflect events occurring after the Company filed its 2023 Annual Report. Information contained in the Exhibits should be read in conjunction with and as a supplement to information contained in the 2023 Annual Report. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Exhibit Description 99.1 Report of Independent Registered Public Accounting Firm (PCAOB ID 688) (incorporated herein by reference to the Financial Statements included in the Form S-1 filed by the Company on December 12, 2024) 99.2 Consolidated Balance Sheets (incorporated herein by reference to the Financial Statements included in the Form S-1 filed by the Company on December 12, 2024) 99.3 Consolidated Statements of Operations (incorporated herein by reference to the Financial Statements included in the Form S-1 filed by the Company on December 12, 2024) 99.4 Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit (incorporated herein by reference to the Financial Statements included in the Form S-1 filed by the Company on December 12, 2024) 99.5 Consolidated Statements of Cash Flows (incorporated herein by reference to the Financial Statements included in t

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CALIDI BIOTHERAPEUTICS, INC. Dated: January 10, 2025 By: /s/ Andrew Jackson Name: Andrew Jackson Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR